Negative in Ames, in vitro chromosomal aberration, and in vivo rat micronucleus and comet assays
“Ripretinib was not mutagenic in the in vitro bacterial reverse mutation (Ames) test or clastogenic in either the in vitro chromosomal aberrations assay in isolated human lymphocytes or the in vivo micronucleus and comet assays in rats.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Carcinogenicity
Not conducted (advanced cancer indication, ICH S9)
“The lack of carcinogenicity studies is acceptable and according to the ICH S9 guideline.”
Rat EFD: cardiovascular and skeletal fetal malformations at 20 mg/kg (~0.4x clinical exposure)
“At the dose of 20 mg/kg daily (approximately 0.4 times the estimated clinical exposure at 150 mg), fetal malformations associated with the cardiovascular and skeletal systems were observed.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Safety pharmacology
Dog telemetry: heart rate up to +129%, raised diastolic and mean arterial pressure, no QTc effect
“A single dose of ripretinib in beagle dogs resulted in increases in heart rate of up to 129% with secondary decreases in QT and PR intervals, as well as increases in diastolic and mean arterial pressure starting at 7 mg/kg; however, ripretinib did not appear to influence QTc intervals.”
✓ VerifiedFDA multi-discipline review, p. 38Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative